* Fulgent Genetics Inc FLGT.OQ FLGT.O is expected
to show a
fall in quarterly revenue when it reports results on February
23.
* The Temple City California-based company is expected to
report
a 35.2% decrease in revenue to $191.1 million from $294.98
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Fulgent Genetics
Inc is
for earnings of $2.61 per share. For the same quarter last year,
the company reported earnings of $6.20 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Fulgent
Genetics
Inc is $102.5, about 37.7% above its last closing price
of $63.85.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2021 3.25 3.25 3.95 Beat 21.7
Jun. 30 2021 2.78 2.76 2.47 Missed -10.4
Mar. 31 2021 5.82 5.86 6.59 Beat 12.5
Dec. 31 2020 4.30 4.05 6.20 Beat 52.9
Sep. 0.55 0.55 2.08 Beat 277.3
30 2020
Jun. 30 2020 -0.01 -0.02 0.17 Beat 1,044.
4
Mar. 31 2020 0.02 0.02 -0.03 Missed -242.9
Dec. 31 2019 0.04 0.04 Met 1.3
This summary was machine generated February 22 at 03:04 GMT.
All figures in US dollars unless otherwise stated